Aegerion Pharmaceuticals, Inc. · Cambridge, MA United States (NASDAQ: AEGR)
| 101 Main St., Ste. 1850 | Phone: 617-500-7867 |
| Cambridge, MA | Fax: 908-541-1155 |
| 02142 | |
| United States | 
Map This Company |
Aegerion Pharmaceuticals, Inc. Rankings
| Russell 2000 (June 2011) |
Company Description
Bad cholesterol, beware! Aegerion Pharmaceuticals is hot on your trail. The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Cutting LDL levels may add years to patients' lives and reduce the risk of cardiovascular events. Aegerion's lead development candidates are protein inhibitors that aim to block cholesterol production in the liver and intestine. The company filed to go public (for the second time) in 2010. It began trading late in the year after raising about $42 million through its IPO.
Aegerion Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: AEGR Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 33 |
Executives
13 executives listed for Aegerion Pharmaceuticals, Inc.'s Cambridge, MA location.
| Chairman | David Scheer | |
|---|---|---|
| CEO and Director | Marc Beer | |
| President | William Lewis |